243 related articles for article (PubMed ID: 30481294)
21. Dysregulation of ErbB Receptor Trafficking and Signaling in Demyelinating Charcot-Marie-Tooth Disease.
Lee SM; Chin LS; Li L
Mol Neurobiol; 2017 Jan; 54(1):87-100. PubMed ID: 26732592
[TBL] [Abstract][Full Text] [Related]
22. Perk Ablation Ameliorates Myelination in S63del-Charcot-Marie-Tooth 1B Neuropathy.
Musner N; Sidoli M; Zambroni D; Del Carro U; Ungaro D; D'Antonio M; Feltri ML; Wrabetz L
ASN Neuro; 2016; 8(2):. PubMed ID: 27095827
[TBL] [Abstract][Full Text] [Related]
23. New evidence for secondary axonal degeneration in demyelinating neuropathies.
Moss KR; Bopp TS; Johnson AE; Höke A
Neurosci Lett; 2021 Jan; 744():135595. PubMed ID: 33359733
[TBL] [Abstract][Full Text] [Related]
24. Niacin-mediated Tace activation ameliorates CMT neuropathies with focal hypermyelination.
Bolino A; Piguet F; Alberizzi V; Pellegatta M; Rivellini C; Guerrero-Valero M; Noseda R; Brombin C; Nonis A; D'Adamo P; Taveggia C; Previtali SC
EMBO Mol Med; 2016 Dec; 8(12):1438-1454. PubMed ID: 27799291
[TBL] [Abstract][Full Text] [Related]
25. Schwann Cell and the Pathogenesis of Charcot-Marie-Tooth Disease.
Murakami T; Sunada Y
Adv Exp Med Biol; 2019; 1190():301-321. PubMed ID: 31760652
[TBL] [Abstract][Full Text] [Related]
26. A new mouse model of Charcot-Marie-Tooth 2J neuropathy replicates human axonopathy and suggest alteration in axo-glia communication.
Shackleford G; Marziali LN; Sasaki Y; Claessens A; Ferri C; Weinstock NI; Rossor AM; Silvestri NJ; Wilson ER; Hurley E; Kidd GJ; Manohar S; Ding D; Salvi RJ; Feltri ML; D'Antonio M; Wrabetz L
PLoS Genet; 2022 Nov; 18(11):e1010477. PubMed ID: 36350884
[TBL] [Abstract][Full Text] [Related]
27. TACE (ADAM17) inhibits Schwann cell myelination.
La Marca R; Cerri F; Horiuchi K; Bachi A; Feltri ML; Wrabetz L; Blobel CP; Quattrini A; Salzer JL; Taveggia C
Nat Neurosci; 2011 Jun; 14(7):857-65. PubMed ID: 21666671
[TBL] [Abstract][Full Text] [Related]
28. Aberrant Neuregulin 1/ErbB Signaling in Charcot-Marie-Tooth Type 4D Disease.
Jiang LT; Chen YH; Huang JH; Tong WF; Jin LJ; Li LX
Mol Cell Biol; 2022 Jul; 42(7):e0055921. PubMed ID: 35708320
[TBL] [Abstract][Full Text] [Related]
29. Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A.
Perea J; Robertson A; Tolmachova T; Muddle J; King RH; Ponsford S; Thomas PK; Huxley C
Hum Mol Genet; 2001 May; 10(10):1007-18. PubMed ID: 11331611
[TBL] [Abstract][Full Text] [Related]
30. Motor and sensory neuropathy due to myelin infolding and paranodal damage in a transgenic mouse model of Charcot-Marie-Tooth disease type 1C.
Lee SM; Sha D; Mohammed AA; Asress S; Glass JD; Chin LS; Li L
Hum Mol Genet; 2013 May; 22(9):1755-70. PubMed ID: 23359569
[TBL] [Abstract][Full Text] [Related]
31. Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy.
Fledrich R; Abdelaal T; Rasch L; Bansal V; Schütza V; Brügger B; Lüchtenborg C; Prukop T; Stenzel J; Rahman RU; Hermes D; Ewers D; Möbius W; Ruhwedel T; Katona I; Weis J; Klein D; Martini R; Brück W; Müller WC; Bonn S; Bechmann I; Nave KA; Stassart RM; Sereda MW
Nat Commun; 2018 Aug; 9(1):3025. PubMed ID: 30072689
[TBL] [Abstract][Full Text] [Related]
32. Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy.
Schiza N; Georgiou E; Kagiava A; Médard JJ; Richter J; Tryfonos C; Sargiannidou I; Heslegrave AJ; Rossor AM; Zetterberg H; Reilly MM; Christodoulou C; Chrast R; Kleopa KA
Brain; 2019 May; 142(5):1227-1241. PubMed ID: 30907403
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of Schwann cell myelin formation by K252a in the Trembler-J mouse dorsal root ganglion explant culture.
Liu N; Varma S; Shooter EM; Tolwani RJ
J Neurosci Res; 2005 Feb; 79(3):310-7. PubMed ID: 15605381
[TBL] [Abstract][Full Text] [Related]
34. Disruption of Endosomal Sorting in Schwann Cells Leads to Defective Myelination and Endosomal Abnormalities Observed in Charcot-Marie-Tooth Disease.
McLean JW; Wilson JA; Tian T; Watson JA; VanHart M; Bean AJ; Scherer SS; Crossman DK; Ubogu E; Wilson SM
J Neurosci; 2022 Jun; 42(25):5085-5101. PubMed ID: 35589390
[TBL] [Abstract][Full Text] [Related]
35. Ndrg1 in development and maintenance of the myelin sheath.
King RH; Chandler D; Lopaticki S; Huang D; Blake J; Muddle JR; Kilpatrick T; Nourallah M; Miyata T; Okuda T; Carter KW; Hunter M; Angelicheva D; Morahan G; Kalaydjieva L
Neurobiol Dis; 2011 Jun; 42(3):368-80. PubMed ID: 21303696
[TBL] [Abstract][Full Text] [Related]
36. Oxydative phosphorylation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy.
Ravera S; Nobbio L; Visigalli D; Bartolucci M; Calzia D; Fiorese F; Mancardi G; Schenone A; Morelli A; Panfoli I
J Neurochem; 2013 Jul; 126(1):82-92. PubMed ID: 23578247
[TBL] [Abstract][Full Text] [Related]
37. Pathology of a mouse mutation in peripheral myelin protein P0 is characteristic of a severe and early onset form of human Charcot-Marie-Tooth type 1B disorder.
Rünker AE; Kobsar I; Fink T; Loers G; Tilling T; Putthoff P; Wessig C; Martini R; Schachner M
J Cell Biol; 2004 May; 165(4):565-73. PubMed ID: 15148307
[TBL] [Abstract][Full Text] [Related]
38. Ndrg1-deficient mice exhibit a progressive demyelinating disorder of peripheral nerves.
Okuda T; Higashi Y; Kokame K; Tanaka C; Kondoh H; Miyata T
Mol Cell Biol; 2004 May; 24(9):3949-56. PubMed ID: 15082788
[TBL] [Abstract][Full Text] [Related]
39. Laminin 211 inhibits protein kinase A in Schwann cells to modulate neuregulin 1 type III-driven myelination.
Ghidinelli M; Poitelon Y; Shin YK; Ameroso D; Williamson C; Ferri C; Pellegatta M; Espino K; Mogha A; Monk K; Podini P; Taveggia C; Nave KA; Wrabetz L; Park HT; Feltri ML
PLoS Biol; 2017 Jun; 15(6):e2001408. PubMed ID: 28636612
[TBL] [Abstract][Full Text] [Related]
40. Schwann cells and the pathogenesis of inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease).
Berger P; Niemann A; Suter U
Glia; 2006 Sep; 54(4):243-57. PubMed ID: 16856148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
